Made Here, Bought Elsewhere: Why WHO Prequalification Was CERVAVAC's Missing Key

A GOOD VACCINE NEEDS A PASSPORT TO TRAVEL

Here's what's actually happening. An HPV vaccine works by showing the immune system the virus's outer shell without the virus inside. Scientists make the main shell protein, called L1, which assembles itself into empty particles that look like the virus from the outside but carry no genetic material and cannot cause infection.

The body learns to recognise that shell and produces antibodies, so a real infection is blocked later. Think of it as a mannequin dressed in the virus's coat. The immune system learns the coat. But the analogy has a limit: protection works only against the types whose coats it has seen.

CERVAVAC is quadrivalent, covering HPV 6 and 11, which cause most genital warts and HPV 16 and 18, which drive a large share of cervical cancers. Gardasil-9 covers more types.

Why a

licensed vaccine still couldn't be bought CERVAVAC was approved by India's drug regulator in July 2022. So why did India's national programme, launched on 28 February 2026 for about 1.15 crore 14-year-old girls, start with Merck's Gardasil-4?

The answer is a gateway that has nothing to do with whether a vaccine works in India. WHO prequalification is a separate quality check: WHO reviews the data, tests samples and inspects the factories. It is not a licence to sell.

Its value is that it makes a vaccine eligible for purchase by UN agencies and GAVI. India's launch was supported by a 250 million dollar GAVI grant and GAVI procurement requires prequalification. CERVAVAC did not have it at the time; it received it effective 25 September 2026.

In short, India had a domestic vaccine but could not use it in the GAVI-funded programme until it held that international quality certificate.

Where

India now stands globally Before CERVAVAC, every prequalified HPV vaccine was made abroad: Cervarix and Gardasil by Western companies, Cecolin and Walrinvax by Chinese companies and Gardasil-9. China reached this milestone before India.

The Serum Institute, the world's largest vaccine maker by doses, already holds prequalification for many vaccines, but for HPV it was playing catch-up. What changes now is choice. Prequalification does not automatically put CERVAVAC into India's programme; that depends on evidence, price, supply and logistics.

But a second prequalified option made in India gives the government more competition and more supply security and it gives low-income countries a new source. The stakes are high. India records roughly 80,000 cervical cancer deaths a year, about a quarter of the global total.

WHO's elimination goal requires 90% of girls fully vaccinated by age 15. More than 80 lakh doses had been given by September 2026, which is a strong start but still short of the target cohort. For the GS3 answer on biotechnology and health, carry this insight: India's vaccine strength now depends less on making more doses and more on securing internationally verified quality, because that verification is what opens markets and programmes.